美敦力旗下糖尿病业务MiniMed拟在美国IPO，估值目标79亿美元

Group 1 - MiniMed Group, a subsidiary of Medtronic, aims for a maximum valuation of $7.86 billion in its upcoming IPO, marking a significant step in the plan to spin off its diabetes business [1] - The IPO plans to issue 28 million shares at a price range of $25 to $28 per share, with a maximum fundraising target of $784 million [1] - MiniMed is a leader in diabetes care, producing insulin pumps, blood glucose monitoring systems, and sensors, and has over 40 years of experience in insulin pump manufacturing [1] Group 2 - Medtronic's decision to spin off MiniMed comes nearly 25 years after acquiring the business for approximately $3.3 billion, with the division facing regulatory concerns over quality management and cybersecurity in recent years [2] - Despite strong revenue growth driven by the 780G insulin pump and sensor upgrades, MiniMed has recorded net losses for three consecutive years, indicating that investors will seek a clear path to profitability [2] - Medtronic plans to fully spin off MiniMed six months after the IPO, with Goldman Sachs, Bank of America Securities, Citigroup, and Morgan Stanley serving as joint book-running managers for the IPO [2]